Don't want ads? Subscribe or login now.

Cephalon, Mylan, Ranbaxy Ink Combined $65.8M Provigil Deal

Law360 (March 26, 2019, 11:03 PM EDT) -- Proposed consumer classes have reached a $65.8 million deal in a suit claiming Mylan and Ranbaxy participated in pay-for-delay deals with Cephalon to prevent the sale of generic versions of the narcolepsy drug Provigil, they told a Pennsylvania federal court Tuesday.

Under the proposed deal, Cephalon Inc. would pay $48 million, Mylan Inc. would pay $14.4 million and Sun Pharmaceutical Industries Ltd. — as successor in interest to Ranbaxy Laboratories Ltd. — would pay $3.5 million to end the claims from consumers claiming violations to antitrust and unjust enrichment laws.

The cash would flow to two classes of thousands of consumers...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Read the full article

Already a subscriber? Click here to login